Project Grant R01AG095675
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $805,573 project grant to The Regents of the University of California, San Francisco to investigate the impact of m6A RNA modifications in Alzheimer's disease and related tauopathies. The grant will support research to uncover changes in m6A RNA modifications and their functional consequences in post-mortem brain tissue from subjects with Alzheimer's disease and other tauopathies,...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $913,225 project grant to St. Jude Children's Research Hospital Inc. The grant will fund research to systematically characterize the U1 small nuclear ribonucleoprotein (U1 SNRNP) and its role in RNA splicing dysfunction, which has been identified as a key event in the pathogenesis of Alzheimer's disease (AD) and related dementias. The research aims to build on the organization's...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $848,286 to the University of South Florida to conduct research on the role of N6-methyladenosine (m6A) RNA modifications in Alzheimer's disease (AD). The key objectives are to: 1) Create a high-resolution map of m6A sites in the brains of older adults, 2) Identify specific m6A alterations associated with AD and its clinical/pathological features, and 3) Elucidate how m6A dysregulation may...
- This federal Project Grant award of $839,933 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate the role of N6-methyladenosine (m6A) RNA modifications in microglial dysfunction and Alzheimer's disease (AD) pathogenesis. The project aims to systematically map m6A modification landscapes in microglia isolated from human brain tissue and human induced pluripotent stem cell-derived microglial models. The researchers will also use CRISPR-based...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $848,993.00 to examine tRNA modifications in Alzheimer's disease and related dementias (ADRD). The research aims to investigate how changes in the tRNA epitranscriptome and tRNA translation dynamics contribute to protein misfolding and proteotoxic stress in ADRD. The project will run from September 15, 2025 to May 31, 2030 and is being conducted by the...
- The National Institute on Aging (NIA) awarded a $773,816 project grant under the Aging Research federal grant program (CFDA 93.866) to the University of California, Irvine (UCI) to conduct comparative studies on new tau-directed Alzheimer's disease (AD) and AD-related dementias (ADRD) mouse models and human AD/ADRD brain tissues. The project aims to generate single-cell spatial proteo-transcriptomics maps to molecularly characterize aberrant RNA splicing and abnormal protein products in specific...
- The National Institute on Aging (NIA), under the Department of Health and Human Services, awarded a $852,273 Project Grant titled "Genetic Mapping of M6A and Pseudouridine RNA Modifications in the Aging Human Brain and Their Impact on Alzheimer's Disease" to The Trustees of Columbia University in the City of New York. The project, which runs from September 1, 2025 to May 31, 2030, aims to investigate the role of RNA modifications in Alzheimer's disease through an innovative integration...
- This Project Grant award of $660,908 was provided by the National Institute on Aging (CFDA 93.866, Aging Research) to Brandeis University. The project aims to expand on previous research demonstrating that certain circular RNAs (circRNAs) can regulate lifespan and health span. Specifically, the research will: 1) determine the mechanisms behind circRNAs that promote aging, 2) examine the extent and requirements for circRNA translation and its relationship to aging, and 3) define the...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
- This $3,360,074 federal Project Grant was awarded on September 15, 2025 by the National Institute on Aging (NIA) under the Aging Research grant program (CFDA 93.866). The grant is funding research led by the University of Pennsylvania to develop short RNA therapeutics that can combat TDP-43 proteinopathy, a key pathological feature of several devastating neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. The research aims to...
The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), has awarded a $595,769 project grant to The University of Kentucky Research Foundation. The grant, effective from September 15, 2025 to August 31, 2030, will support research to investigate the role of RNA modifications on the translation of circular RNAs in Alzheimer's disease (AD). The project aims to determine the mechanism of inosine-mediated translation of AD-relevant circular RNAs, assess the pathogenetic relevance of modification-dependent circular RNA translation in human brain tissue, and evaluate the role of circular RNA-encoded proteins in promoting tau aggregation. The research seeks to advance scientific understanding of the impact of RNA modifications on brain aging and AD/ADRD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $595.8k | 9/9/25 |